Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

23Andme Holding Co (ME)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow 23Andme Holding Co's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.36 -0.03    -8.69%
16:00:29 - Closed. Currency in USD ( Disclaimer )
After Hours
0.36
-0.00
-0.00%
17:33:01 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 6,139,132
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 0.35 - 0.40
23Andme Holding Co 0.36 -0.03 -8.69%

23Andme Holding Co Company Profile

 
Get an in-depth profile of 23Andme Holding Co, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Providers & Services
SectorHealthcare
Employees

793

Equity Type

ORD

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company’s therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Contact Information

Address 349 Oyster Point Boulevard
South San Francisco, 94080
United States
Phone 650 938 6300
Fax -

Top Executives

Name Age Since Title
Richard H. Scheller 70 2015 Director
Patrick S. Chung - 2021 Independent Director
Valerie C. Montgomery Rice 61 2021 Independent Director
Roelof Frederik Botha 50 2021 Independent Director
Neal Mohan 49 2021 Independent Director
Peter J. Taylor 64 2021 Independent Director
Sandra R. Hernandez 66 2021 Independent Director
Anne Wojcicki - 2006 Co-Founder, CEO, President & Chair of the Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ME Comments

Write your thoughts about 23Andme Holding Co
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Aug 22, 2023 1:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
is this company bankcrupted?
wonseok choi
wonseok choi Aug 08, 2022 11:23AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
kidding me?
Jake SJ Wu
Jake SJ Wu Jun 13, 2022 11:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
⭕️
wonseok choi
wonseok choi Mar 03, 2022 5:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
nobody interested in 23
Георги Петров
Георги Петров Oct 26, 2021 9:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀🚀🚀
claudia risi
claudia risi Oct 23, 2021 5:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
23andMe Agrees to Acquire Lemonaid Health. The purchase price is 400m, of which 25% cash and 75% in shares calculated on a fixed value of 8.82 per share. So 34m new shares to be issued.
Scott Ornelas
Jatslo Oct 20, 2021 2:04PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ME (T) 1 10.19
Amir HM
Amir HM Oct 20, 2021 10:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$20 soon?
fish and chips mate
fish and chips mate Oct 19, 2021 1:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What's the news boys?
Giuseppe Giannachi
Giuseppe Giannachi Oct 15, 2021 9:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why the surge?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email